search
Back to results

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

Primary Purpose

HIV Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Needs assessment followed by tailored intervention
Sponsored by
Centers for Disease Control and Prevention
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring HIV infection, antiretroviral therapy, adherence, pediatric

Eligibility Criteria

5 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Families with a child between the ages of 5 and 12 years old who is HIV-infected and who receives care at participating hospitals Informed consent for and assent from the child Informed consent for the primary caregiver (person responsible for most of the child's medication delivery) must be obtained. The parent/legal guardian must be able to give informed consent and willing to comply with protocol requirements. The HIV-infected child must be currently prescribed an antiretroviral therapy regimen. Exclusion Criteria: The child or caregiver cannot respond to self-report questions because of cognitive impairments. The child receives home health care in which the home health care aide dispenses all of the child's medication (essentially resulting in directly observed therapy for that child). The child and/or the caretaker does not speak English or Spanish.

Sites / Locations

  • Children's National Medical Center
  • Howard University Hospital, Department of Pediatrics
  • Jacobi Medical Center

Outcomes

Primary Outcome Measures

Improved adherence to antiretroviral treatment regimen

Secondary Outcome Measures

Improved viral load
Improved CD4 count

Full Information

First Posted
August 24, 2005
Last Updated
September 26, 2012
Sponsor
Centers for Disease Control and Prevention
Collaborators
Jacobi Medical Center, Children's National Research Institute, Howard University
search

1. Study Identification

Unique Protocol Identification Number
NCT00134602
Brief Title
Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children
Official Title
An Intervention to Promote Adherence to Antiretroviral Medications Among HIV-infected Children 5-12 Years of Age
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
April 2003 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
October 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centers for Disease Control and Prevention
Collaborators
Jacobi Medical Center, Children's National Research Institute, Howard University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to develop and evaluate an intervention to promote adherence to HIV medications among children 5-12 years of age. It compares changes in antiretroviral (ARV) adherence between the EIG (enhanced intervention group) and an MIG (minimal intervention group) from baseline to 4 months post-intervention. Secondary outcomes include examining whether improvement in adherence to a medication regimen is associated with improved health outcomes (i.e., viral load, CD4 counts, etc.); identifying and evaluating predictors and/or mediators of adherence; studying the feasibility of electronic recording in measuring adherence in an HIV-infected pediatric population; and evaluating the relationship between the amount of intervention received (i.e., number of hours/number of sessions) and changes in adherence.
Detailed Description
The objective of this research is to develop and evaluate an intervention to promote adherence to HIV-medications among children aged 5-12 years. The research will be conducted at Jacobi Medical Center in the Bronx, NY; Children's National Medical Center in Washington, DC; and at Howard University Hospital in Washington, DC. The research will employ a randomized case control study design. Participants (dyads composed of an HIV-infected child and his/her primary caregiver) will be recruited from eligible families within each site's HIV clinic. After the study is explained and informed consent and assent (where applicable) are obtained, participants will be randomly assigned to either the enhanced intervention group (cases) or the minimal intervention group (controls). Participants assigned to the enhanced intervention group will receive a multi-component intervention, specifically tailored to their family's needs, which includes a maximum of 24 hours of contact conducted over a period of up to 12-weeks, and a 1-3 hour booster session approximately six weeks after the intervention phase is completed. The enhanced intervention will be coordinated by an onsite Adherence Coordinator (AC) and implemented primarily by the AC or another member of the study staff. Participants assigned to the comparison group will receive a minimal intervention that will consist of an educational video and health education pamphlets about general health. All participants will continue to receive the standard-of-care at their respective sites during the study period. Assessments of all participants will be done at baseline (Assessment A), 1 month (Assessment B), and 4 months (Assessment C) following the intervention. Each assessment will include an interview to collect the following information from families: socio-demographic data; parental/child report of child's medication taking or adherence (self-reported adherence); mental health functioning (of parents and child, using standardized measures); HIV (of parents) and medication knowledge (of parents and child); medical review of child's hospital chart. The baseline assessment of adherence to medications will include electronic recording of medication taking via a MEMS® cap done over a four-week period. Ongoing electronic assessment of adherence will occur for the duration of the study. Pharmacy refill data will also be obtained for a portion of the study participants for whom data are available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV infection, antiretroviral therapy, adherence, pediatric

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (false)

8. Arms, Groups, and Interventions

Intervention Type
Behavioral
Intervention Name(s)
Needs assessment followed by tailored intervention
Primary Outcome Measure Information:
Title
Improved adherence to antiretroviral treatment regimen
Secondary Outcome Measure Information:
Title
Improved viral load
Title
Improved CD4 count

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Families with a child between the ages of 5 and 12 years old who is HIV-infected and who receives care at participating hospitals Informed consent for and assent from the child Informed consent for the primary caregiver (person responsible for most of the child's medication delivery) must be obtained. The parent/legal guardian must be able to give informed consent and willing to comply with protocol requirements. The HIV-infected child must be currently prescribed an antiretroviral therapy regimen. Exclusion Criteria: The child or caregiver cannot respond to self-report questions because of cognitive impairments. The child receives home health care in which the home health care aide dispenses all of the child's medication (essentially resulting in directly observed therapy for that child). The child and/or the caretaker does not speak English or Spanish.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Wiznia, MD
Organizational Affiliation
Jacobi Medical Center, Bronx, NY
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tamara Rakusan, MD
Organizational Affiliation
Children's National Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sohail Rana, MD
Organizational Affiliation
Howard University Hospital, Pediatrics Department
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's National Medical Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Howard University Hospital, Department of Pediatrics
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20060
Country
United States
Facility Name
Jacobi Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

We'll reach out to this number within 24 hrs